Pediatric Constipation Medication

  • Author: Stephen Borowitz, MD; Chief Editor: Carmen Cuffari, MD   more...
 
Updated: Feb 1, 2012
 

Medication Summary

In several randomized trials, laxatives have been shown to be beneficial in the treatment of chronic childhood constipation.[21, 22] Studies have also shown that polyethylene glycol,[23] mineral oil, magnesium hydroxide, and lactulose are effective and can be used for prolonged time periods without risk.

The key to pharmacotherapy is to use a sufficient amount of laxative to produce the desired effect. The intermittent use of stimulant laxatives may be necessary in some children; however, routine usage of these agents in young children is not generally recommended. Continuous laxative therapy may be required for a number of months until the child extinguishes the association between pain and the passage of bowel movements.

Next

Osmotic Laxatives

Class Summary

Osmotic laxatives produce an osmotic effect in the colon that results in distention and promotes peristalsis.

Polyethylene glycol (MiraLAX, Dulcolax Balance)

 

Polyethylene glycol (PEG) is a long chain of ethylene glycol molecules that results in an extremely large molecule. This agent is very poorly absorbed and functions as an osmotic laxative. The powders are tasteless and odorless and dissolve completely in nearly all liquids including water.

These agents often can also be used as purgatives in preparation for colonoscopy. At very large dosages, PEG is occasionally difficult to take and its usage may be associated with nausea, bloating, abdominal cramps, and vomiting.

Magnesium hydroxide (Philips' Milk of Magnesia, Fleet Pedia-Lax)

 

Magnesium is a divalent cation that is maximally absorbed in the distal small intestine. At low concentrations, magnesium appears to absorb by a saturable carrier-mediated process influenced by vitamin D. At higher concentrations, magnesium absorption appears to occur largely by diffusion and is quite inefficient. Increased serum magnesium levels may release cholecystokinin, which stimulates gastrointestinal motility and secretion; this may explain why some children experience abdominal cramping.

Magnesium is mostly flavorless but has a thick, chalky texture. It is made more palatable when mixed with a fluid (eg, milk, chocolate milk).

Lactulose (Constulose, Enulose, Generlac, Kristalose)

 

Lactulose is a synthetic, nonabsorbable disaccharide that is available as a 70% solution. This agent is generally very well tolerated and tastes sweet. Lactulose formulation contains 10 g lactulose/15 mL of oral solution.

Sorbitol

 

Sorbitol is an alcohol of glucose that is largely nonabsorbable. This agent is available as a 70% solution. As with lactulose, sorbitol is generally well tolerated and tastes quite sweet.

Magnesium citrate (Citroma)

 

Magnesium is a divalent cation that is maximally absorbed in the distal small intestine. At low concentrations, magnesium appears to absorb by a saturable carrier-mediated process influenced by vitamin D. At higher concentrations, magnesium absorption appears to occur largely by diffusion and is quite inefficient. Increased serum magnesium levels may release cholecystokinin, which stimulates gastrointestinal motility and secretion; this may explain why some children experience abdominal cramping.

Sodium acid phosphate (OsmoPrep, Visicol)

 

Phosphate is a divalent anion largely absorbed in the proximal small intestine. When this agent is administered as an enema, only small amounts are absorbed such that the phosphate functions as an osmotic agent. Each 15 mL contains 7.2 g monobasic sodium phosphate monohydrate and 2.7 g dibasic sodium phosphate heptahydrate.

Previous
Next

Lubricants

Class Summary

Lubricating agents soften stools and decrease water absorption from the gastrointestinal tract. They may also promote salt and water secretion by the colon.

Mineral oil (Kondremul)

 

Mineral oil is a nonabsorbable fat that softens stool and decreases water absorption, partly by its metabolism in the colon to hydroxy fatty acids. This agent is largely tasteless and has an oily consistency that is made more palatable if it is cold or mixed into a fluid (eg, orange juice). When mineral oil is taken in high doses, many children experience seepage of orange oil into their underwear, which can produce perianal pruritus.

Previous
Next

Stimulant Laxatives

Class Summary

Stimulant laxatives increase peristaltic activity in the gastrointestinal tract. Most of these agents also stimulate salt and water secretion in the colon.

Senna (Ex-Lax, Senokot, Fletcher's, Little Tummys)

 

Sennosides are plant alkaloids that stimulate colonic salt and water secretion and promote colonic motility. At higher doses, these agents often produce abdominal cramping. Long-term use in animals has not been associated with any evidence of cathartic colon, tachyphylaxis, or secondary hyperaldosteronism.

Bisacodyl (Dulcolax, Bisco-Lax)

 

Bisacodyl is a colorless and odorless compound that is very poorly absorbed. This agent can be administered orally or rectally. Bisacodyl increases colonic peristalsis and stimulates salt and water secretion.

Previous
Next

Stool Softeners

Class Summary

Stool softening agents allow incorporation of water and fat into the stool, causing the stool to soften.

Docusate sodium (Colace, Docu-Soft, Diocto, DSS)

 

Docusate sodium is used to avoid straining during defecation. This agent allows incorporation of water and fat into the stool, causing it to soften.

Previous
Next

Stool Softeners in Combination With Stimulants

Class Summary

Emollient stool softeners cause stool to soften. Stimulants increase peristaltic activity in the gastrointestinal tract. Most of both these types of agents also promote salt and water secretion by the colon.

Senna concentrate/docusate (Peri-Colace, Senokot, Dok Plus)

 

Docusate sodium allows incorporation of water and fat into the stool, causing it to soften. Casanthranol is an anthraquinone stimulant hydrolyzed by colonic bacteria into an active compound. Action is usually produced 8-12 hours after administration of this combination.

Previous
 
Contributor Information and Disclosures
Author

Stephen Borowitz, MD  Professor of Pediatrics and Public Health Sciences, Department of Pediatrics, Division of Gastroenterology and Nutrition, University of Virginia School of Medicine

Stephen Borowitz, MD is a member of the following medical societies: American Academy of Pediatrics, American Gastroenterological Association, American Pediatric Society, North American Society for Pediatric Gastroenterology and Nutrition, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Specialty Editor Board

Chris A Liacouras  MD, Director of Pediatric Endoscopy, Division of Gastroenterology and Nutrition, Children's Hospital of Philadelphia; Associate Professor of Pediatrics, University of Pennsylvania School of Medicine

Chris A Liacouras is a member of the following medical societies: American Gastroenterological Association

Disclosure: Nothing to disclose.

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Chief Editor

Carmen Cuffari, MD  Associate Professor, Department of Pediatrics, Division of Gastroenterology/Nutrition, Johns Hopkins University School of Medicine

Carmen Cuffari, MD is a member of the following medical societies: American College of Gastroenterology, American Gastroenterological Association, North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, and Royal College of Physicians and Surgeons of Canada

Disclosure: Nothing to disclose.

References
  1. [Best Evidence] van den Berg MM, Benninga MA, Di Lorenzo C. Epidemiology of childhood constipation: a systematic review. Am J Gastroenterol. Oct 2006;101(10):2401-9. [Medline].

  2. Borowitz SM, Cox DJ, Kovatchev B, et al. Treatment of childhood constipation by primary care physicians: efficacy and predictors of outcome. Pediatrics. Apr 2005;115(4):873-7. [Medline].

  3. [Guideline] North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. Evaluation and treatment of constipation in children: summary of updated recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. Sep 2006;43(3):405-7. [Medline].

  4. Benninga M, Candy DC, Catto-Smith AG, et al. The Paris Consensus on Childhood Constipation Terminology (PACCT) Group. J Pediatr Gastroenterol Nutr. Mar 2005;40(3):273-5. [Medline].

  5. Issenman RM, Hewson S, Pirhonen D, et al. Are chronic digestive complaints the result of abnormal dietary patterns? Diet and digestive complaints in children at 22 and 40 months of age. Am J Dis Child. Jun 1987;141(6):679-82. [Medline].

  6. Loening-Baucke V. Prevalence rates for constipation and faecal and urinary incontinence. Arch Dis Child. Jun 2007;92(6):486-9. [Medline].

  7. Saps M, Sztainberg M, Di Lorenzo C. A prospective community-based study of gastroenterological symptoms in school-age children. J Pediatr Gastroenterol Nutr. Oct 2006;43(4):477-82. [Medline].

  8. Yong D, Beattie RM. Normal bowel habit and prevalence of constipation in primary-school children. In: Ambulatory Child Health. Vol 4. 1998:277-82.

  9. de Araujo Sant Anna AM, Calcado AC. Constipation in school-aged children at public schools in Rio de Janeiro, Brazil. J Pediatr Gastroenterol Nutr. Aug 1999;29(2):190-3. [Medline].

  10. Borowitz SM, Cox DJ, Tam A, et al. Precipitants of constipation during early childhood. J Am Board Fam Pract. May-Jun 2003;16(3):213-8. [Medline].

  11. De Lorijn F, Reitsma JB, Voskuijl WP, et al. Diagnosis of Hirschsprung's disease: a prospective, comparative accuracy study of common tests. J Pediatr. Jun 2005;146(6):787-92. [Medline].

  12. Abrahamian FP, Lloyd-Still JD. Chronic constipation in childhood: a longitudinal study of 186 patients. J Pediatr Gastroenterol Nutr. Jun 1984;3(3):460-7. [Medline].

  13. Loening-Baucke V. Polyethylene glycol without electrolytes for children with constipation and encopresis. J Pediatr Gastroenterol Nutr. Apr 2002;34(4):372-7. [Medline].

  14. Bekkali NL, van den Berg MM, Dijkgraaf MG, et al. Rectal fecal impaction treatment in childhood constipation: enemas versus high doses oral PEG. Pediatrics. Dec 2009;124(6):e1108-15. [Medline].

  15. Miller MK, Dowd MD, Friesen CA, Walsh-Kelly CM. A Randomized Trial of Enema Versus Polyethylene Glycol 3350 for Fecal Disimpaction in Children Presenting to an Emergency Department. Pediatr Emerg Care. Jan 20 2012;[Medline].

  16. Pijpers MA, Tabbers MM, Benninga MA, Berger MY. Currently recommended treatments of childhood constipation are not evidence based: a systematic literature review on the effect of laxative treatment and dietary measures. Arch Dis Child. Feb 2009;94(2):117-31. [Medline].

  17. Corkins MR. Are diet and constipation related in children?. Nutr Clin Pract. Oct 2005;20(5):536-9. [Medline].

  18. Iacono G, Cavataio F, Montalto G, et al. Intolerance of cow's milk and chronic constipation in children. N Engl J Med. Oct 15 1998;339(16):1100-4. [Medline].

  19. Lloyd B, Halter RJ, Kuchan MJ, et al. Formula tolerance in postbreastfed and exclusively formula-fed infants. Pediatrics. Jan 1999;103(1):E7. [Medline].

  20. Vandenplas Y, Benninga M. Probiotics and functional gastrointestinal disorders in children. J Pediatr Gastroenterol Nutr. Apr 2009;48 Suppl 2:S107-9. [Medline].

  21. Muller-Lissner SA. Adverse effects of laxatives: fact and fiction. Pharmacology. Oct 1993;47 Suppl 1:138-45. [Medline].

  22. Schiller LR. Clinical pharmacology and use of laxatives and lavage solutions. J Clin Gastroenterol. Jan 1999;28(1):11-8. [Medline].

  23. Dupont C, Leluyer B, Amar F, et al. A dose determination study of polyethylene glycol 4000 in constipated children: factors influencing the maintenance dose. J Pediatr Gastroenterol Nutr. Feb 2006;42(2):178-85. [Medline].

  24. Khan S, Campo J, Bridge JA, et al. Long-term outcome of functional childhood constipation. Dig Dis Sci. Jan 2007;52(1):64-9. [Medline].

Previous
Next
 
Plain abdominal radiograph that demonstrates stool throughout the colon.
This table differentiates functional constipation from Hirschsprung disease.
This unprepared single-contrast barium enema demonstrates a transition zone consistent with Hirschsprung disease.
The images illustrate normal anorectal manometry with relaxation of the internal anal sphincter in response to rectal distention.
This image delineates common withholding behaviors in young children.
Contrast enema of a patient with megasigmoid and impacted stool.
Contrast enema in a patient in whom the rectosigmoid was resected.
Position for enema administration in an infant.
Another position for enema administration.
Administration of an enema.
Incorrect enema administration. The enema is administered against stool impaction and cannot be successful.
Enema administration with a tube.
Enema with inflated Foley balloon catheter.
Administration of an enema against impacted stool.
Administration of an enema against fecal impaction.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.